# CERO catalysts: CERO THERAPEUTICS HOLDINGS, INC. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/cero/catalysts

> CERO THERAPEUTICS HOLDINGS, INC. (CERO) has no upcoming catalysts in this calendar. The latest recorded is the CER-1236 trial start, Sep 2025.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, half-year only, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | CERO THERAPEUTICS HOLDINGS, INC. |
| Ticker | CERO (OTC) |
| SEC CIK | 1870404 |
| SIC | 2836 |
| SEC filings | https://sec-api.dev/companies/cero |

## Cash runway

Cash $456K as of 2026-09-30; quarterly burn $3.0M; about 0.5 months of runway at that rate (XBRL company facts, accession 0001213900-26-119677).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| June 28, 2024 | [CER-1236 NDA/BLA submission](https://sec-api.dev/pdufa/cer-1236) | CERO |  | completed | "On June 28, 2024, the Company submitted an Investigational New Drug Application ("IND") for its product candidate, CER-1236, to FDA." ([SEC registration statement (S-1)](https://www.sec.gov/Archives/edgar/data/1870404/000121390025066152/ea0244907-s1_cero.htm)) |
| July 26, 2024 | [CERO THERAPEUTICS HOLDINGS, INC. complete response letter (CRL)](https://sec-api.dev/companies/cero/catalysts) | CERO |  | completed, complete response letter | "We received the Hold Letter on July 26, 2024 and submitted a complete response letter to the FDA on October 21, 2024 in which we requested a meeting to address the FDA's questions." ([SEC registration statement (S-1)](https://www.sec.gov/Archives/edgar/data/1870404/000121390025066152/ea0244907-s1_cero.htm)) |
| 1H 2025 | [CER-1236 NDA/BLA submission](https://sec-api.dev/pdufa/cer-1236) | CERO |  | scheduled | "As we draw closer to introducing CER-1236 into the clinic, we continue to make additional pre-clinical progress with CER-1236 and presently intend to file an additional Investigational New Drug Application for CER-1236 in solid tumors, including ovarian and non-small cell lung cancers, in the first half of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1870404/000121390024106240/ea022355901ex99-1_cero.htm)) |
| Q1 2025 | [CER-1236 trial start](https://sec-api.dev/pdufa/cer-1236) | CERO |  | scheduled | "Now this team will turn its attention to expeditiously deploying our resources in anticipation of what we believe will be a first quarter 2025 start for our Phase 1 trial, and we look forward to sharing future program updates," concluded Ehrlich." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1870404/000121390024099354/ea022142102ex99-1_cero.htm)) |
| May 2025 | [CER-1236 trial start](https://sec-api.dev/pdufa/cer-1236) | CERO |  | completed | "Based on the preclinical data regarding the use of CER-1236 T cells to combat hematologic malignancies, we began our Phase 1 clinical trial in May 2025." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1870404/000121390026044040/ea0285271-10k_cero.htm)) |
| May 20, 2025 | [CERO THERAPEUTICS HOLDINGS, INC. trial start](https://sec-api.dev/companies/cero/catalysts) | CERO |  | completed | "First patient dosed on May 20, 2025 ⎼ No dose - limiting toxicity at 28 days ⎼ Encouraging PK response" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1870404/000121390025090107/ea025816601ex99-1_cero.htm)) |
| Sep 2025 | [CER-1236 trial start](https://sec-api.dev/pdufa/cer-1236) | CERO |  | completed | "In September 2025, the Company announced that it had dosed the third patient in the starting dose cohort of its Phase 1 clinical trial evaluating CER-1236 in AML." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1870404/000121390026119677/ea0311517-10q_cero.htm)) |

## Drugs

- [CER-1236](https://sec-api.dev/pdufa/cer-1236): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/cero/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "CERO catalysts: CERO THERAPEUTICS HOLDINGS, INC. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/cero/catalysts

```bibtex
@misc{secapidev_companies_cero_catalysts_20261116,
  title        = {CERO catalysts: CERO THERAPEUTICS HOLDINGS, INC. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/cero/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_cero_catalysts_20261116","title":"CERO catalysts: CERO THERAPEUTICS HOLDINGS, INC. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/cero/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
